Point72 Asset Management L.P. Sells 122,609 Shares of Sanofi (NASDAQ:SNY)

Point72 Asset Management L.P. cut its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 58.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 88,879 shares of the company's stock after selling 122,609 shares during the quarter. Point72 Asset Management L.P.'s holdings in Sanofi were worth $5,122,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. GFS Advisors LLC lifted its stake in shares of Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after buying an additional 11,655 shares during the last quarter. Legacy Capital Wealth Partners LLC grew its position in Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company's stock worth $1,399,000 after purchasing an additional 12,942 shares during the last quarter. Icon Wealth Advisors LLC increased its holdings in shares of Sanofi by 7,954.4% during the 3rd quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company's stock worth $16,873,000 after purchasing an additional 289,144 shares during the period. Envestnet Portfolio Solutions Inc. raised its stake in shares of Sanofi by 15.2% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company's stock valued at $5,673,000 after purchasing an additional 15,439 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Sanofi in the 3rd quarter worth approximately $8,728,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Friday. Citigroup upgraded Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi has a consensus rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Stock Performance

Shares of NASDAQ SNY remained flat at $48.46 during trading hours on Monday. 831,963 shares of the company traded hands, compared to its average volume of 2,055,608. The firm has a market cap of $122.98 billion, a P/E ratio of 24.72, a PEG ratio of 1.23 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The firm has a fifty day moving average of $51.90 and a two-hundred day moving average of $52.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the previous year, the business earned $2.55 EPS. The business's quarterly revenue was up 12.3% compared to the same quarter last year. As a group, sell-side analysts expect that Sanofi will post 4.27 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.